Amendments to the Claims

Please amend Claims 1, 10 and 11. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A capsule comprising a porous membrane formed by a polyelectrolyte complex which encapsulates cells which express [[a]] cytochrome P450 [[gene]] as a cell membrane-bound protein, wherein the porous membrane of the capsule is permeable to prodrug molecules and the ~~cytochrome P450 gene and the cytochrome P450 expressed by the gene~~ cells are retained within the capsule.

2. (Original) The capsule according to Claim 1, wherein the capsule material comprises a complex formed from cellulose sulphate and polydimethyldiallylammonium.

3. (Previously presented) The capsule according to Claim 1, wherein said capsule comprises cellulose sulphate.

4. (Previously presented) The capsule according to Claim 1, wherein said capsule comprises polydimethyldiallylammonium.

5. Canceled.

6. (Previously presented) The capsule according to Claim 1, wherein the capsule comprises a cellulose based material.

7. (Previously presented) The capsule according to Claim 1, wherein the polyelectrolyte complex comprises a sulphate group.

8. (Original) A pharmaceutical composition comprising the capsule according to Claim 1.

9. (Previously presented) The capsule according to Claim 1 wherein the cytochrome P450 is cytochrome 2B1.

10. (Currently amended) A method for ablation of tumour cells, comprising administering locally into said tumor cells or close to the site of said tumor cells, prodrug molecules and a capsule wherein the capsule comprises a porous membrane formed by a polyelectrolyte complex which encapsulates cells which express [[a]] cytochrome P450 [[gene]] as a cell membrane-bound protein, wherein the porous membrane of the capsule is permeable to the prodrug molecules, the ~~cytochrome P450 gene and the cytochrome P450 expressed by the gene~~ cells are retained within the capsule, and the prodrug molecules are converted into active drug molecules by cytochrome P450 and thereby ablate the tumor cells.

11. (Currently amended) A method of treating a tumor comprising administering to a subject in need thereof a therapeutically effective amount of a capsule and, either simultaneously or with a time span, a prodrug which is activated by cytochrome P450, wherein the capsule comprises a porous membrane formed by a polyelectrolyte complex which encapsulates cells which express [[a]] cytochrome P450 [[gene]] as a cell membrane-bound protein, the porous membrane of the capsule is permeable to the prodrug molecules, the ~~cytochrome P450 gene and the cytochrome P450 expressed by the gene~~ cells are retained within the capsule and the capsule is introduced into the tumor or next to the tumor.

12. (Previously presented) The method according to Claim 11, wherein the capsule is administered by a route of administration selected from the group consisting of: injection into the target cells, implantation into the target cells and combinations thereof, wherein the prodrug is administered systemically, locally or systemically and locally.

13. (Original) The method according to Claim 11, wherein the target cells are cells of breast tumours and/or pancreatic tumours.

14. (Original) The method according to Claim 11, wherein the prodrug is cyclophosphamide and/or ifosfamide.

15. (Original) A pharmaceutical kit comprising capsules according to Claim 1 and a prodrug which is activated by cytochrome P450.

16. (Previously presented) The pharmaceutical kit according to Claim 15, wherein the capsules and the prodrug are formulated so that the capsules, which are administered into a target or next to the target, and the prodrug can be administered by different routes of administration.

17. (Previously presented) The pharmaceutical kit according to Claim 16, comprising the capsule in the form suitable for an injection or implantation into the target organs or next to the target organ, and the prodrug in the form suitable for systemic or local administration.

18. (Original) The pharmaceutical kit according to Claim 15 comprising the capsules in the form suitable for the implantation into and/or next to breast cancer tissue or pancreatic cancer tissue.

19. (Original) The pharmaceutical kit according to Claim 15 comprising cyclophosphamide and/or ifosfamide as the prodrug.

20. (Previously presented) The method according to Claim 10 wherein the prodrug is selected from the group consisting of cyclophosphamide and ifosfamide.

21. (Original) The capsule according to Claim 9 wherein the cytochrome P450 2B1 is derived from rat liver.

22. (Previously presented) The capsule according to Claim 1 wherein the cytochrome P450 is encoded by a mammalian expression vector.